NEW YORK (GenomeWeb News) – Foundation Medicine today announced a deal with AstraZeneca aimed at predicting a patient's response or resistance to targeted medicines.

The firms are partnering to identify genomic mutations in cancer-related tumor genes that may prove helpful to AstraZeneca in developing new therapies for patients. Foundation Medicine also was granted right of first negotiation for developing potential diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Popular Mechanics reports that Caltech researchers have built a prototype nanobot using DNA.

The Sacramento Bee writes that direct-to-consumer genetic testing connected a woman to sperm donor-conceived half siblings.

In PLOS this week: gene expression catalog for sheep, viral diversity among respiratory samples from camels, and more.